首页> 外文期刊>Medical decision making: An international journal of the Society for Medical Decision Making >Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group
【24h】

Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group

机译:大型癌症临床试验合作组织SWOG中使用信息分析价值进行实时优先决策的方法的开发和评估

获取原文
获取原文并翻译 | 示例
       

摘要

Objective. Value of information (VOI) analyses can align research with areas with the greatest potential impact on patient outcome, but questions remain concerning the feasibility and acceptability of these approaches to inform prioritization decisions. Our objective was to develop a process for calculating VOI in "real time" to inform trial funding decisions within SWOG, a large cancer clinical trials group. Methods. We developed an efficient and scalable VOI modeling approach using a selected sample of 9 randomized phase II/III trial proposals from the Breast, Gastrointestinal, and Genitourinary Disease Committees reviewed by SWOG's leadership between 2008 and 2013. There was bidirectional communication between SWOG investigators and the research team throughout the modeling development. Partial expected value of sample information for the treatment effect evaluated by the proposed trial's primary endpoint was calculated using Monte Carlo simulation. Results. We derived prior uncertainty in the treatment effect estimate from the sample size calculations. Our process was feasible for 8 of 9 trial proposals and efficient: the time required of 1 researcher was <1 week per proposal. We accommodated stakeholder input primarily by deconstructing VOI metrics into expected health benefits and incremental healthcare costs and assuming treatment decisions within our simulations were based on health benefits. Following customization, feedback from over 200 SWOG members was positive regarding the overall VOI framework, specific retrospective results, and potential for VOI analyses to inform future trial proposal evaluations. Conclusions. We developed an efficient and customized process to calculate the expected VOI of cancer clinical trials that is feasible for use in decision making and acceptable to investigators. Prospective use and evaluation of this approach is currently underway within SWOG.
机译:目的。信息价值(VOI)分析可以使研究与对患者结局具有最大潜在影响的领域保持一致,但是仍然存在有关这些方法的可行性和可接受性的信息,这些方法可为优先级决策提供依据。我们的目标是开发一种“实时”计算VOI的方法,以为大型癌症临床试验组SWOG内的试验资金决策提供依据。方法。我们从2008年至2013年期间由SWOG领导层审查的乳腺癌,胃肠道和泌尿生殖系统疾病委员会的9个随机II / III随机试验方案的选定样本中,开发出了一种有效且可扩展的VOI建模方法。SWOG研究人员和研究人员之间存在双向沟通研究团队在整个建模开发过程中。使用蒙特卡洛模拟法计算了通过拟议试验的主要终点评估的治疗效果的样本信息的部分期望值。结果。我们从样本量计算得出治疗效果估计值的先验不确定性。我们的流程对于9个试验提案中的8个是可行的,并且非常有效:每个提案要求1名研究人员的时间少于1周。我们主要通过将VOI指标分解为预期的健康益处和增加的医疗保健费用,并假设模拟中的治疗决策基于健康益处来适应利益相关者的意见。经过定制后,来自200多名SWOG成员的反馈对整个VOI框架,特定的回顾性结果以及VOI分析的潜力提供了积极的反馈,这些信息可为将来的试验方案评估提供信息。结论我们开发了一种高效且定制的过程来计算癌症临床试验的预期VOI,该VOI可用于决策制定并为研究者所接受。 SWOG当前正在对此方法进行预期的使用和评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号